Aim To investigate the effects of carbocisteine treatment in the reduction of frequency of productive cough episodes, preventing disease progression and improving the quality of life as well as the tolerability of the administered treatment and patient compliance during the study. Methods This observational, non-interventional, multicenter, cohort study included 501 patients with chronic obstructive pulmonary disease (COPD) who were administrated carbocisteine capsules 375 mg and followed up during the next 15 days. The patients were observed at 3 points, baseline and two additional assessments. General clinical condition of patients, along with the spirometry testing at all three points were examined. Thr quality of life was assessed on the 1st and 3rd observation with Leicester Cough Questionnaire. Tolerability and patient compliance were measured throughout the study. Results There was a significant change of forced expiratory volume in 1 second (FEV1) status between the second and third observation (p=0.002). Examination of general symptoms showed a statistically significant reduction in cough by 74.9%, in sputum production by 48.5%, in dyspnea by 29% and in fatigue by 50%. After the administration of carbocisteine the median value of overall quality of life was 3.79 (3.63-3.89). Conclusion 375mg carbocisteine capsules were found to be effective and well-tolerated in the treatment of COPD, with a small percentage of reported mild adverse reactions and with a significant improvement of quality of life.
Antó J, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Resp J. 2001. p. 982–94.
2.
Vijayan V. Chronic obstructive pulmonary disease.
3.
Indian J Med Res. 2013. p. 251–69.
4.
Health statistics annual Federation of Bosnia and Herzegovina. Maligraf; 2014.
5.
Rycroft C, Heyes A, Lanza L, Becker E. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012. p. 457–94.
6.
Raherison C, Girodet P. Epidemiology of COPD. Eur Respir Rev. 2009. p. 213–21.
7.
Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin A, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016. p. 625–37.
8.
Tatsumi K, Fukuchi Y. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2007. p. 1884–6.
9.
Čatić T, Kapo B, Duranović L, Krstović G, Mehić M. Translation and adaptation of Leichester Cough Questionnaire (LCQ) for use in Bosnia and Herzegovina as quality of life measure instrument in acute and chronic cough. Pharmacia. 2016. p. 5–10.
10.
Decramer M, Janssens W. Mucoactive therapy in COPD. Eur Respir Rev. 2010. p. 134–40.
11.
Balsamo R, Lanata L, Egan C. Mucoactive drugs. Eur Respir Rev. 2010. p. 127–33.
12.
Hooper C, Calvert J. The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008. p. 659–69.
13.
Seemungal T, Donaldson G, Paul E, Bestall J, Jeffries D, Wedzicha J. Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 1998. p. 1418–22.
14.
French C, Irwin R, Curley F, Krikorian C. Impact of chronic cough on quality of life. Arch Intern Med. 1998. p. 1657–61.
15.
Zheng J, Kang J, Huang S, Chen P, Yao W, Yang L, et al. Effect of carbocisteine on acute exacerbations of chronic obstructive pulmonary disease (PEACE study): a randomized placebo-controlled study. Lancet. 2008. p. 2013–8.
16.
Poole P, Black P. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 2001. p. 1271.
17.
French C, Irwin R, Fletcher K, Adams T. Evaluation of a cough-specific quality-of-life questionnaire. Chest. 2002. p. 1123–31.
18.
Efikasnost karbocistina u tretmanu hronične opstruktivne plućne bolesti i njegov utjecaj na kvalitet života.
Centar za porodičnu medicinu, Dom zdravlja Kalesija, Kalesija, 2 Dom zdravlja Kantona Sarajevo, Sarajevo, 3 Bosnalijek d.d., Sarajevo, 4 Medicinski fakultet Univerziteta u Sarajevu, Sarajevo SAŽETAK Cilj Ispitati efekte terapije s karbocisteinom u smanjenju učestalosti epizoda produktivnog kašlja, sprečavanju progresije bolesti i poboljšanju kvalitete života.
21.
Metode Ova opservacijska, neintervencijska, multicentrična, kohortna studija uključivala je 501 pacijenta s hroničnom opstruktivnom plućnom bolesti (HOPB), kojima su ordinirane kapsule karbocisteina od 375 mg, te su praćeni narednih 15 dana. Pacijenti su se pratili kroz tri mjerenja: nulto i dva kontrolna. Opće kliničko stanje i spirometrija su praćeni tokom sva tri mjerenja. Kvalitet života je procjenjivan na prvom i trećem mjerenju, koristeći Leicester Cough Questionnaire.
22.
Ispitivanje općih simptoma pokazalo je statistički značajno smanjenje kašlja za 74.9%, iskašljaja za 48.5%, dispneje za 29% i zamora za 50%. Nakon terapije karbocisteinom srednja vrijednost kvalitete života.
23.
Zaključak Primjena karbocistein kapsula od 375 mg pokazala se efikasnom, i dobro podnošljivom u tretmanu HOPB-a, sa rijetkim neželjenim efektima te značajnim poboljšanjem kvalitete života pacijenata.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
